Purified Modified mRNA for Non-Integrating Cell Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating induced pluripotent stem cells (iPSCs) are inefficient and often integrate exogenous DNA into the genome, leading to unpredictable outcomes and potential cancer risks, while non-viral delivery techniques are inefficient and require extended time for iPSC formation.
Innovation Solution
The use of purified single-strand mRNA molecules, modified with nucleosides such as pseudouridine, 5-methylcytosine, and 2′-O-methyluridine, to reprogram eukaryotic cells by contacting them with these mRNA molecules that encode reprogramming factors, thereby avoiding genome integration and enhancing efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral delivery methods (retrovirus or lentivirus) are used to deliver reprogramming factors, then delivery efficiency is high, but genome integration occurs leading to unpredictable outcomes and cancer risks
Solution Approach 1:
The patent extracts the reprogramming function from integrated viral DNA and delivers it via non-integrating mRNA molecules. The mRNA encodes reprogramming factors that are translated in the cytoplasm without requiring genomic integration, thereby achieving high delivery efficiency while eliminating cancer risks associated with viral genome integration.
Solution Approach 2:
The patent uses mRNA as an intermediary carrier to deliver reprogramming factors. Instead of using viral vectors that integrate into the genome, the mRNA serves as a temporary mediator that is translated into proteins and then degrades naturally, achieving efficient delivery without permanent genomic modification.
2Reliability
If non-viral delivery techniques (plasmid transfection) are used to deliver reprogramming factors, then genome integrity is maintained, but delivery efficiency is low and reprogramming takes extended time
Solution Approach 1:
The patent changes the physical and chemical parameters of the delivery system by using chemically modified nucleosides (pseudouridine, 5-methylcytosine, 2′-O-methyluridine) in the mRNA. These modifications enhance mRNA stability, translation efficiency, and cellular uptake, thereby achieving high reprogramming efficiency while maintaining genome integrity through non-integrating delivery.
Solution Approach 2:
The patent employs composite mRNA structures containing multiple modified nucleosides (pseudouridine, 5-methylcytosine, and 2′-O-methyluridine) combined with optimized 5′ caps and poly(A) tails. This composite design enhances delivery efficiency and reprogramming speed while maintaining non-integrating properties that preserve genome integrity.
3Ease of manufacture
If unmodified canonical nucleosides are used in mRNA, then mRNA synthesis is simple, but the mRNA activates RNA sensors and triggers unintended immune responses
Solution Approach 1:
The patent modifies the chemical parameters of nucleosides by incorporating pseudouridine, 5-methylcytosine, and 2′-O-methyluridine into the mRNA sequence. These chemical modifications prevent recognition by cellular RNA sensors (such as PKR and RIG-I), thereby eliminating immune response activation while maintaining relatively simple in vitro transcription synthesis procedures.
Data Source
AI summary
The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.